The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer. This study also includes patients with primary peritoneal cancer.
Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
Bahía Blanca, Argentina
Buenos Aires, Argentina
Ramos Mejía, Argentina
Salta, Argentina